HRP20020159B1 - Multi-dose erythropoietin formulations - Google Patents

Multi-dose erythropoietin formulations

Info

Publication number
HRP20020159B1
HRP20020159B1 HR20020159A HRP20020159A HRP20020159B1 HR P20020159 B1 HRP20020159 B1 HR P20020159B1 HR 20020159 A HR20020159 A HR 20020159A HR P20020159 A HRP20020159 A HR P20020159A HR P20020159 B1 HRP20020159 B1 HR P20020159B1
Authority
HR
Croatia
Prior art keywords
dose erythropoietin
erythropoietin formulations
formulations
dose
composition
Prior art date
Application number
HR20020159A
Other languages
English (en)
Croatian (hr)
Inventor
Gayed Atef
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of HRP20020159A2 publication Critical patent/HRP20020159A2/hr
Publication of HRP20020159B1 publication Critical patent/HRP20020159B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HR20020159A 1999-07-22 2000-07-21 Multi-dose erythropoietin formulations HRP20020159B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19821699P 1999-07-22 1999-07-22
PCT/US2000/040446 WO2001007075A2 (en) 1999-07-22 2000-07-21 Multi-dose erythropoietin formulations

Publications (2)

Publication Number Publication Date
HRP20020159A2 HRP20020159A2 (en) 2003-06-30
HRP20020159B1 true HRP20020159B1 (en) 2007-08-31

Family

ID=22732468

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020159A HRP20020159B1 (en) 1999-07-22 2000-07-21 Multi-dose erythropoietin formulations

Country Status (25)

Country Link
US (1) US7432360B2 (https=)
EP (1) EP1200115B9 (https=)
JP (1) JP2003517462A (https=)
KR (1) KR100693263B1 (https=)
CN (2) CN1371284A (https=)
AT (1) ATE304863T1 (https=)
AU (1) AU777397B2 (https=)
BR (1) BR0012667A (https=)
CA (1) CA2378945C (https=)
CZ (1) CZ302750B6 (https=)
DE (1) DE60022759T2 (https=)
DK (1) DK1200115T3 (https=)
EA (1) EA006220B1 (https=)
EE (1) EE200200037A (https=)
ES (1) ES2248110T3 (https=)
HK (1) HK1050318A1 (https=)
HR (1) HRP20020159B1 (https=)
HU (1) HUP0202246A3 (https=)
IL (2) IL147755A0 (https=)
NO (1) NO20020303L (https=)
NZ (1) NZ516735A (https=)
PL (1) PL202945B1 (https=)
RS (1) RS50355B (https=)
WO (1) WO2001007075A2 (https=)
ZA (1) ZA200200742B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520777A (ja) 1999-07-22 2003-07-08 アベンティス・ファーマスーティカルズ・インコーポレイテツド 防腐医薬製剤
ME00673B (me) 2000-05-15 2011-12-20 Hoffmann La Roche Nova farmaceutska smjesa
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
UA89630C2 (ru) * 2004-03-26 2010-02-25 Янссен Фармацевтика Н.В. Схема комбинированного дозирования для эритропоэтина
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
BRPI0606784B1 (pt) * 2005-02-03 2018-07-31 Clariant Produkte (Deutschland) Gmbh Conservantes
JP2011116752A (ja) * 2009-10-29 2011-06-16 Jcr Pharmaceuticals Co Ltd エリスロポエチン含有水性液剤
KR101805087B1 (ko) 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
ES2982752T3 (es) * 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489837A (en) * 1968-07-11 1970-01-13 Leroy J Hyman Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPH0651637B2 (ja) * 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
JP2532025B2 (ja) * 1993-07-23 1996-09-11 株式会社林原生物化学研究所 新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
EP0803255A4 (en) * 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
EP0784979A3 (en) * 1996-01-19 1999-03-03 Eli Lilly And Company Obesity protein formulations
CA2265743A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
JPH1112193A (ja) * 1997-06-19 1999-01-19 Sankyo Co Ltd ヒトカルシトニン含有水溶液製剤
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine

Also Published As

Publication number Publication date
KR20020011143A (ko) 2002-02-07
EP1200115B1 (en) 2005-09-21
EE200200037A (et) 2003-04-15
NO20020303D0 (no) 2002-01-21
IL147755A0 (en) 2002-08-14
CN1371284A (zh) 2002-09-25
JP2003517462A (ja) 2003-05-27
DE60022759D1 (de) 2006-02-02
HUP0202246A2 (en) 2002-10-28
US7432360B2 (en) 2008-10-07
WO2001007075A2 (en) 2001-02-01
ATE304863T1 (de) 2005-10-15
CZ302750B6 (cs) 2011-10-19
YU4702A (sh) 2005-06-10
WO2001007075A3 (en) 2001-10-04
HRP20020159A2 (en) 2003-06-30
CZ2002264A3 (cs) 2002-06-12
ES2248110T3 (es) 2006-03-16
AU777397B2 (en) 2004-10-14
EA200200073A1 (ru) 2002-08-29
DK1200115T3 (da) 2006-01-16
NO20020303L (no) 2002-03-21
PL202945B1 (pl) 2009-08-31
HUP0202246A3 (en) 2010-01-28
RS50355B (sr) 2009-11-10
NZ516735A (en) 2004-01-30
EP1200115B9 (en) 2006-01-18
ZA200200742B (en) 2003-06-25
US20050267033A1 (en) 2005-12-01
CA2378945A1 (en) 2001-02-01
EA006220B1 (ru) 2005-10-27
CA2378945C (en) 2010-02-23
KR100693263B1 (ko) 2007-03-13
DE60022759T2 (de) 2006-06-22
AU7137400A (en) 2001-02-13
HK1050318A1 (zh) 2003-06-20
BR0012667A (pt) 2002-07-02
CN101091792A (zh) 2007-12-26
PL353569A1 (en) 2003-12-01
EP1200115A2 (en) 2002-05-02
IL147755A (en) 2009-11-18

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
TR200100054T2 (tr) Paroksetin metansülfonat
ATE312843T1 (de) Neues cyclosporin mit verbesserter wirkung
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
NO20024891D0 (no) Farmasöytiske sammensetninger
DK1175149T3 (da) Desinficerende sammensætning baseret på H2O2, syrer og metaliioner
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
FR2805465B1 (fr) Nouvelles compositions pharmaceutique ou dietetiques a base de champignons
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
DE60303967D1 (de) 9a-azalide mit entzündungshemmender wirkung
SE9802208D0 (sv) Novel compounds
BRPI0209619B8 (pt) agente promotor de crescimento capilar
HRP20020159B1 (en) Multi-dose erythropoietin formulations
DE60321594D1 (de) Synergistische zusammensetzungen
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
DK1135239T3 (da) Formuleringer til trækonservering
ATE235832T1 (de) Hartkaramellen mit verbesserter lagerstabilität
SE0001916D0 (sv) Novel formulation
NZ336043A (en) Use of COMT inhibitors for preventing diabetic vascular dysfunctions or neuropathy
HRP20000703B1 (hr) Stabilni pripravci koji sadrže levosimendan i alginsku kiselinu
DE59903598D1 (de) Wirkstoffhaltige polyetherblockamide
ID26929A (id) Fungisida
IT1307736B1 (it) Ossopiperazinil derivati e composizioni fotostabilizzate.
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
DE69813833T2 (de) 4-cyano-4-deformylsordarizin-derivate

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: HMR PHARMA INC., US

PPPP Transfer of rights

Owner name: AVENTIS HOLDINGS INC., US

Owner name: AVENTISUB II INC., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20110716

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20120722